Guardant Health Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: Guardant Health Inc. Common Stock is far larger — about 12.9× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 1,297,295). Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Personalis Inc. Common Stock for 0 Days on average.
| GH | PSNL | |
|---|---|---|
Market Cap | $21.74B | $1.69B |
Volume | 1,297,295 | 3,817,236 |
Sector | Health | Health |
52-Week High | $187.22 | $18.38 |
52-Week Low | $64.19 | $5.04 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →